The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke: an international multi-centre, randomised, controlled trial to investigate the safety and efficacy of treatment with intravenous recombinant tissue plasminogen activator (rt-PA) within six hours of onset of acute ischaemic stroke.

Trial Profile

The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke: an international multi-centre, randomised, controlled trial to investigate the safety and efficacy of treatment with intravenous recombinant tissue plasminogen activator (rt-PA) within six hours of onset of acute ischaemic stroke.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Alteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms IST-3
  • Most Recent Events

    • 22 Dec 2016 Results (n=300) assessing baseline angiography features which predict response to intravenous thrombolytics in ischemic stroke using IST-3 trial data, published in the Stroke.
    • 09 Dec 2015 Results published in the Neurology
    • 20 Oct 2015 Results assessing effects of BP and BP-lowering treatment during the first 24 Hours published in the Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top